摘要
PD-L1 has two receptors: PD-1 and CD80. Previous reports assumed that PD-L1 and CD80 interacted in trans, but recent reports showed that only cis PD-L1/CD80 interactions existed, and prevention of cis PD-L1/CD80 interactions on antigen-presenting cells (APCs) reduced antitumor immunity via augmenting PD-L1/PD-1 and CD80/ CTLA4 interactions between T and APCs. Here, using tumor-bearing mice capable of cis and trans or trans only PD-L1/CD80 interactions, we show that trans PD-L1/CD80 interactions do exist between tumor and T cells, and the effects of trans PD-L1/CD80 interactions require tumor cell expression of MHC-I and T cell expression of CD28. The blockade of PD-L1/CD80 interactions in mice with both cis and trans interactions or with only trans interactions augments antitumor immunity by expanding IFN-& gamma;-producing CD8+ T cells and IFN-& gamma;-dependent NOS2-expressing tumor-associated macrophages. Our studies indicate that although cis and trans PD-L1/CD80 interactions may have opposite effects on antitumor immunity, the net effect of blocking PD-L1/CD80 interactions in vivo augments CD8+ T cell-mediated antitumor immunity.
学科与关键词
- Blockade of PD-L1 interaction with CD80 in trans augments anti-tumor immunity by increasing NOS2 in tumor-associated macrophages.Zhang, Yuankun; Song, Qingxiao; Lee, Michael; Tang, Haidong; Cassady, Kaniel; Fu, Yang-Xin; Schones, Dustin E.; Riggs, Arthur; Feng, Ru; Zeng, DefuAnnual Meeting of the American-Association-for-Cancer-Research (AACR), Philadelphia, PA, 2021-04-10 To 2021.
- The primordial differentiation of tumor-specific memory CD8+T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodesHuang, Qizhao; Wu, Xia; Wang, Zhiming; Chen, Xiangyu; Wang, Lisha; Lu, Yijun; Xiong, Dan; Liu, Qiao; Tian, Yuhan; Lin, Huayu; Guo, Junyi; Wen, Shuqiong; Dong, Wei; Yang, Xiaofan; Yuan, Yuchen; Yue, Zhengliang; Lei, Shun; Wu, Qing; Ran, Ling; Xie, Luoyingzi; Wang, Yifei; Gao, Leiqiong; Tian, Qin; Zhou, Xinyuan; Sun, Beicheng*; Xu, Lifan*; Tang, Zhonghui*; Ye, Lilin*Cell, 2022, 185(22): 4049-+.被引 61
- The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancersTang, Qing; Chen, Yun; Li, Xiaojuan; Long, Shunqin; Shi, Yao; Yu, Yaya; Wu, Wanyin*; Han, Ling*; Wang, Sumei*Frontiers in Immunology, 2022, 13: 964442.被引 57
